Family-Building Costs, Barriers and Dropout Rates Associated With Fertility Care
Janet Choi, MD, analyzes fertility care access, balancing the significant benefits of evidence-based reproductive treatment against the economic obstacles that restrict patient utilization of safe, effective interventions known to improve outcomes.
This is a video synopsis/summary of a Population Health Perspectives® involvingJanet Choi, MD.The video discusses the substantial financial barriers to fertility treatment, with costs ranging from $15,000 to $30,000 per in vitro fertilization cycle. A survey found 77% of LGBTQ+ individuals pursuing parenthood worried about family-building costs. Of those lacking adequate insurance, many tapped savings or took loans, adding stress. However, the speaker argues comprehensive coverage reduces patient emotional/financial tolls. Initially skeptical clients realize savings of 25% to 30% over traditional programs, without accounting for boosted recruitment/retention and productivity and lower absenteeism from improved benefits. Janet Choi, MD,maintainsthat adding inclusive fertility coverage costs less than expected, with dividends for diversity, equity and inclusion. With rising infertility prevalence and assisted reproductive technology reliance among LGBTQ+ prospective parents, innovative smart cycle value-based configurations are gaining favor. Such end-to-end individual coverage is superior to limited dollar caps that burden patients withtracking service expenses to fit budgets, distorting clinical decisions. Comprehensive smart cycle benefits ease anxiety about affording prescribed treatments so patients can focus fully on building families.
Video synopsis is AIgenerated and reviewed by Managed Healthcare Executive® editorial staff.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
